In order to treat inflammatory diseases in an effective, safe, long-lasting, and disease-modifying manner, patients require a therapeutic approach that can stop the inflammatory cascade and the consequent metabolic effects. We are currently studying our proprietary non-viral pDNA technology in a number of chronic inflammatory diseases including osteoarthritis (OA), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), facet joint syndrome, and neuropathic pain. We have completed a Phase 2b trial for the use of XT-150 in our lead indication, OA of the knee, and have an ongoing Ph1/2a trial for facet joint syndrome. Of note, next-generation development has the potential to expand tissue targeting specificity and customized delivery to broaden disease targets.